Department of Hematology and Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Department of Obstetrics and Gynecology, Kurashiki Central Hospital, Kurashiki, Japan.
Int J Hematol. 2018 Aug;108(2):203-207. doi: 10.1007/s12185-017-2397-8. Epub 2017 Dec 30.
For pregnant women with essential thrombocythemia (ET), no standard approach for managing the platelet count has been established. We present the cases of two pregnant women with ET treated with interferon (IFN)-alpha. Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events. To clarify the efficacy and safely of IFN alpha for ET during pregnancy, we performed a literature review. A total of 43 pregnant women with ET were ultimately identified from 12 articles and the present cases. IFN-alpha therapy decreased platelet counts to normal levels at birth in many cases, and there were no adverse events that required the discontinuation of IFN-alpha treatment. Overall, 93% of pregnant women with ET gave birth to healthy babies. We consider that, given its efficacy and safety, IFN-alpha therapy is a reasonable treatment option for pregnant women with ET.
对于患有原发性血小板增多症（ET）的孕妇，尚未确立用于管理血小板计数的标准方法。我们介绍了两名接受干扰素（IFN）-α治疗的 ET 孕妇的病例。每个病例均表现出明显的血小板减少，分娩时血小板计数在正常范围内，且无严重不良事件。为了阐明 IFNα在怀孕期间治疗 ET 的疗效和安全性，我们进行了文献复习。最终从 12 篇文章和本病例中确定了 43 例 ET 孕妇。IFN-α治疗使许多患者的血小板计数在分娩时降至正常水平，且没有需要停止 IFN-α治疗的不良事件。总体而言，93%的 ET 孕妇生下了健康的婴儿。我们认为，鉴于其疗效和安全性，IFN-α治疗是 ET 孕妇的合理治疗选择。
